Status:
COMPLETED
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Lead Sponsor:
University of Alberta
Conditions:
Liver Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.
Detailed Description
A total of 70 patients with HCC (mean age: 54.6 years, female/male: 12/58) received a liver transplant and were included in the study. Immunosuppression included de novo sirolimus, low-dose calcineuri...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult patients with hepatocellular (HCC) carcinoma receiving liver transplant
- Exclusion criteria:
- Patients less than 18 years of age
Exclusion
Key Trial Info
Start Date :
December 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00328770
Start Date
December 1 1996
End Date
March 1 2006
Last Update
June 24 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta
Edmonton, Alberta, Canada, T6G 2B7